



Luis Jara-Palomares¹, Remedios Otero-Candelera¹, David Jimenez², Marc Carrier³, Inna Tzorana⁴, Benjamin Brenner⁴, Manuel Monreal⁵.
¹Medical Surgical Unit of Respiratory Diseases, Hospital Virgen del Rocío, CIBERES, Seville, Spain. ²Respiratory Department, Ramón y Cajal Hospital, IRYCIS, Madrid, Spain ³Thrombosis Program, Division of Hematology, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada. ⁴Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel. ⁵ Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol de Badalona. Universidad Católica de Murcia. Spain.

INTRODUCCIÓN

La realización de screening de neo oculta en pacientes con ETV actualmente es controvertida


OBJETIVOS

1. Identificar población de riesgo de desarrollar neoplasia oculta tras ETV
2. Desarrollar Score de neoplasia oculta

MATERIAL Y MÉTODOS

- Registro RIETE
- Casos controles anidados en una cohorte
 - Casos: Neoplasia oculta
 - Controles: No neoplasia

RESULTADOS



	Occult cancer	No cancer	OR (95%CI)	p value
Patients, n	444	5,419		
Clinical characteristics				
Gender (male), n (%)	246 (55)	2,644 (49)	1.30 (1.07-1.58)	0.007
Age > 70 years, n (%)	265 (60)	2,355 (43)	1.93 (1.58-2.35)	<0.001
Weight (kg), mean (DS)	73.9 (14)	76.5 (15)	0.75 (1.04-3.97)	0.001
BMI, mean (DS)	27.6 (4.8)	28.5 (5.2)	0.31 (0.36-1.56)	0.002
Co-morbid diseases, n (%)				
Chronic lung disease	74 (17)	568 (10)	1.71 (1.31-2.23)	<0.001
Chronic heart failure	30 (6.8)	314 (5.8)	1.18 (0.80-1.74)	0.407
Recent major bleeding	9 (2.0)	94 (1.7)	1.17 (0.59-2.34)	0.652
Laboratory findings, n (%)				
Anaemia	154 (35)	1,315 (24)	1.66 (1.35-2.03)	<0.001
Leucocytes >11,000 x 1,000/mm ³	123 (28)	1,321 (24)	1.19 (0.96-1.48)	0.118
Platelet count ≥350,000 x 1,000/mm ³	55 (12)	509 (9.4)	1.36 (1.01-1.83)	0.040
Raised fibrinogen levels	27 (39)	1,029 (41)	0.89 (0.55-1.45)	0.642
Positive D-dimer levels	75 (68)	2,199 (66)	1.09 (0.34-3.52)	0.922
Initial VTE presentation, n (%)				
⊙ DVT	219 (49)	2625 (48)	0.95 (0.76-1.18)	0.868
⊙ Pulmonary embolism	142 (32)	1800 (33)		
⊙ DVT / pulmonary embolism	83 (19)	994 (18)		
Proximal DVT	257 (84)	3113 (86)	0.86 (0.62-1.19)	0.359
Bilateral DVT	20 (6.2)	156 (4.1)	1.54 (0.95-2.49)	0.108
Upper extremity DVT	6 (1.4)	137 (2.5)	0.46 (0.20-1.08)	0.161
Risk factors for VTE, n (%)				
Recent surgery	28 (6.3)	564 (10)	0.58 (0.39-0.86)	0.006
Recent immobility ≥4 days	90 (20)	1094 (20)	1.01 (0.79-1.28)	0.967
Hormonal therapy	8 (1.8)	324 (6.1)	0.29 (0.14-0.58)	<0.001
Recent travel	8 (1.8)	142 (2.7)	0.68 (0.33-1.40)	0.297
Pregnancy/ puerperium	112 (2.1)	0	-	-
None of the above (unprovoked)	310 (70)	3356 (62)	1.42 (1.15-1.75)	0.001
Varicose veins	77 (18)	1182 (22)	0.77 (0.60-0.99)	0.045
Prior VTE	62 (14)	1036 (19)	0.69 (0.52-0.91)	0.007

Site of cancer	Total	<50 years	50-70 years	>70 years
Men, all patients	2,890	662	1,057	1,171
Men, occult cancer, n (%)	246 (8.51)	23 (3.47)	81 (7.66)	142 (12.1)
Lung	63 (2.18)	8 (1.21)	21 (1.99)	34 (2.90)
Prostate	42 (1.45)	1 (0.15)	13 (1.23)	28 (2.39)
Colorectal	29 (1.00)	1 (0.15)	7 (0.66)	21 (1.79)
Bladder	17 (0.59)	0	5 (0.47)	12 (1.02)
Hematologic	13 (0.45)	4 (0.60)	5 (0.47)	4 (0.34)
Stomach	12 (0.42)	0	2 (0.19)	10 (0.85)
Unknown origin	12 (0.42)	0	6 (0.57)	6 (0.51)
Kidney	9 (0.31)	0	5 (0.47)	4 (0.34)
Brain	8 (0.28)	5 (0.76)	1 (0.09)	2 (0.17)
Biliary tract	8 (0.28)	1 (0.60)	2 (0.19)	5 (0.43)
Liver	6 (0.21)	1 (0.60)	3 (0.28)	2 (0.17)
Pancreas	5 (0.17)	0	1 (0.09)	4 (0.34)
Oral/pharyngeal /Larynx	5 (0.17)	0	2 (0.19)	3 (0.26)
Oesophagus	4 (0.14)	0	2 (0.19)	2 (0.17)
Other	13 (0.45)	2 (0.30)	6 (0.57)	5 (0.43)

Multivariable analysis for hidden cancer within 24 months after VTE						
	β	Odds ratio	95% CI		p value	Points
			Lower	Upper		
Underlying conditions						
Male gender	.378	1.46	1.19	1.79	<0.001	+1
Age >70 years	.642	1.90	1.55	2.33	<0.001	+2
Chronic lung disease	.338	1.40	1.07	1.84	.015	+1
Anaemia	.539	1.71	1.38	2.13	<0.001	+2
Platelets ≥350	.334	1.40	1.03	1.90	.034	+1
Risk factors for VTE						
Postoperative	-.722	.49	.32	.73	<0.001	-2
Prior VTE	-.392	.68	.51	.89	.006	-1

Site of cancer	Total	<50 years	50-70 years	>70 years
Women, all patients	2,973	695	679	1,599
Women, occult cancer, n(%)	198 (6.66)	17 (2.45)	40 (5.89)	141 (8.82)
Colorectal	38 (1.28)	3 (0.43)	6 (0.88)	29 (1.81)
Breast	23 (0.77)	1 (0.14)	6 (0.88)	16 (1.00)
Uterus	18 (0.61)	3 (0.43)	2 (0.29)	13 (0.81)
Hematologic	17 (0.57)	0	3 (0.44)	14 (0.88)
Unknown origin	15 (0.50)	1 (0.14)	2 (0.29)	12 (0.75)
Pancreas	15 (0.50)	0	3 (0.44)	12 (0.75)
Stomach	12 (0.40)	0	2 (0.29)	10 (0.63)
Ovary	12 (0.40)	3 (0.43)	6 (0.88)	3 (0.19)
Lung	9 (0.30)	3 (0.43)	1 (0.15)	5 (0.31)
Bladder	9 (0.30)	0	1 (0.15)	8 (0.50)
Kidney	8 (0.27)	1 (0.14)	3 (0.44)	4 (0.25)
Brain	5 (0.17)	0	2 (0.29)	3 (0.19)
Biliary tract	4 (0.13)	0	0	4 (0.25)
Other	13 (0.44)	2 (0.29)	3 (0.44)	8 (0.50)

Men, <50 years	Men, 50-70 years	Men, >70 years
Cancer: 23/662 (3.5%)	Cancer: 81/1057 (7.7%)	Cancer: 142/1171 (12%)
Score ≤2 points: 3.1%	Score ≤2 points: 6.5%	Score ≤2 points: 8.6%
Score >2 points: 6.9%	Score >2 points: 16%	Score >2 points: 13%
Women, <50 years		
Cancer: 17/695 (2.4%)	Cancer: 40/679 (5.9%)	Cancer: 141/1599 (8.8%)
Score ≤2 points: 1.9%	Score ≤2 points: 5.7%	Score ≤2 points: 8.6%
Score >2 points: 15%	Score >2 points: 11.1%	Score >2 points: 9.3%

CONCLUSIONES

Este estudio contribuye a identificar cáncer oculto en los pacientes con ETV, y ha desarrollado una escala para identificar a los pacientes con mayor riesgo. Esta escala, sin embargo, debe ser validada.